Dose escalation in lung cancer: Have we gone full circle?

The Lancet Oncology

Volumn 16, Issue 2, 2015, Pages 125-127

  Faivre Finn, Corinne ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL; ANTINEOPLASTIC AGENT;

CANCER CONTROL; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; DOSE RESPONSE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LUNG FIBROSIS; NON SMALL CELL LUNG CANCER; NOTE; ORGANS AT RISK; OVERALL SURVIVAL; QUALITY CONTROL; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME TO TREATMENT; TREATMENT FAILURE; ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; LUNG NEOPLASMS; MALE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84921887535     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70001-X     Document Type: Note

References (9)

1. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015, published online Jan 16. http://dx.doi.org/10.1016/S1470-2045(14)71207-0.
2. Bradley JD, Paulus R, Komaki R, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab forstage III non-small cell lung cancer: results on radiation dose in RTOG 0617. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 750.
3. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999, 24:31-37.
4. Curran WJ, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
5. Chang AJ, Bradley JD Clinical perspectives on dose escalation for non-small-cell lung cancer. Clin Lung Cancer 2010, 11:299-302.
6. Modelmog D, Rahlenbeck S, Trichopoulos D Accuracy of death certificates: a population-based, complete-coverage, one-year autopsy study in East Germany. Cancer Causes Control 1992, 3:541-546.
7. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat cell carcinoma of the lung: preliminary report by the Radiation Therapy Oncology Group. Cancer 1980, 45:2744-2753.
8. Eaton BR, Pugh SL, Bradley JD, et al. The effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer treated with chemoradiation: a report of the Radiation Therapy Oncology Group (RTOG) 0617. Proc Am Soc J Clin Oncol 2014, 32(suppl). abstr 5s.
9. Faivre-Finn C, Snee M Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned. Int J Radiat Oncol Biol Phys 2014, 90:487-489.